158 related articles for article (PubMed ID: 17135231)
1. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.
Naline E; Trifilieff A; Fairhurst RA; Advenier C; Molimard M
Eur Respir J; 2007 Mar; 29(3):575-81. PubMed ID: 17135231
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.
Sturton RG; Trifilieff A; Nicholson AG; Barnes PJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):270-5. PubMed ID: 17916760
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Battram C; Charlton SJ; Cuenoud B; Dowling MR; Fairhurst RA; Farr D; Fozard JR; Leighton-Davies JR; Lewis CA; McEvoy L; Turner RJ; Trifilieff A
J Pharmacol Exp Ther; 2006 May; 317(2):762-70. PubMed ID: 16434564
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
5. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi.
Molimard M; Naline E; Zhang Y; Le Gros V; Begaud B; Advenier C
Eur Respir J; 1998 Mar; 11(3):583-8. PubMed ID: 9596106
[TBL] [Abstract][Full Text] [Related]
6. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus.
Naline E; Zhang Y; Qian Y; Mairon N; Anderson GP; Grandordy B; Advenier C
Eur Respir J; 1994 May; 7(5):914-20. PubMed ID: 7914176
[TBL] [Abstract][Full Text] [Related]
7. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
8. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
9. A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.
Summerhill S; Stroud T; Nagendra R; Perros-Huguet C; Trevethick M
J Pharmacol Toxicol Methods; 2008; 58(3):189-97. PubMed ID: 18652905
[TBL] [Abstract][Full Text] [Related]
10. Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.
Scola AM; Chong LK; Suvarna SK; Chess-Williams R; Peachell PT
Br J Pharmacol; 2004 Jan; 141(1):163-71. PubMed ID: 14662724
[TBL] [Abstract][Full Text] [Related]
11. Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea.
Bergendal A; Lindén A; Lötvall J; Skoogh BE; Löfdahl CG
Br J Pharmacol; 1995 Apr; 114(7):1478-82. PubMed ID: 7606351
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
13. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol.
Nials AT; Ball DI; Butchers PR; Coleman RA; Humbles AA; Johnson M; Vardey CJ
Eur J Pharmacol; 1994 Jan; 251(2-3):127-35. PubMed ID: 8149969
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.
Lindén A; Bergendal A; Ullman A; Skoogh BE; Löfdahl CG
Thorax; 1993 May; 48(5):547-53. PubMed ID: 8100652
[TBL] [Abstract][Full Text] [Related]
15. Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model.
Mohammed SP; Taylor CV; Weyman-Jones CB; Mather ME; Vendy K; Dougall IG; Young A
Pulm Pharmacol Ther; 2000; 13(6):287-92. PubMed ID: 11061983
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.
Lindén A; Rabe KF; Löfdahl CG
Lung; 1996; 174(1):1-22. PubMed ID: 8746998
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase.
Teschemacher A; Lemoine H
J Pharmacol Exp Ther; 1999 Mar; 288(3):1084-92. PubMed ID: 10027845
[TBL] [Abstract][Full Text] [Related]
18. [Inquiry into the mechanism of long-acting bronchodilators].
Bao Y; Lemoine H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Jun; 20(3):191-6. PubMed ID: 11367704
[TBL] [Abstract][Full Text] [Related]
19. Effects of two beta 3-adrenoceptor agonists, SR 58611A and BRL 37344, and of salbutamol on cholinergic and NANC neural contraction in guinea-pig main bronchi in vitro.
Martin CA; Naline E; Manara L; Advenier C
Br J Pharmacol; 1993 Dec; 110(4):1311-6. PubMed ID: 7905768
[TBL] [Abstract][Full Text] [Related]
20. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?
Lombardi D; Cuenoud B; Krämer SD
Eur J Pharm Sci; 2009 Dec; 38(5):533-47. PubMed ID: 19819331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
